• Friday, August 26, 2022 @ 12:00 am

AC BioScience, a Biopôle-based clinical stage biotech company, successfully closed a fourth seed round for CHF 2.5 million. The company is pioneering the development of novel therapies in immuno-oncology and tumor vascular normalization with the first exploratory clinical trial Phase 2a for metastatic pancreatic cancer patients to start in early 2023. This bridge funding precedes a series A round to fund the planned clinical trials for their two lead investigational drugs.

You may also be interested in